Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 43 entries
Sorted by: Best Match Show Resources per page
Fecal Microbiota Transplant for Refractory .

Open forum infectious diseases

Wang T, Kraft CS, Woodworth MH, Dhere T, Eaton ME.
PMID: 29450212
Open Forum Infect Dis. 2018 Jan 15;5(2):ofy016. doi: 10.1093/ofid/ofy016. eCollection 2018 Feb.

No abstract available.

Cite
Wang T, Kraft CS, Woodworth MH, et al. Fecal Microbiota Transplant for Refractory . Open Forum Infect Dis. 2018;5(2):ofy016doi: 10.1093/ofid/ofy016.
Wang, T., Kraft, C. S., Woodworth, M. H., Dhere, T., & Eaton, M. E. (2018). Fecal Microbiota Transplant for Refractory . Open forum infectious diseases, 5(2), ofy016. https://doi.org/10.1093/ofid/ofy016
Wang, Tiffany, et al. "Fecal Microbiota Transplant for Refractory ." Open forum infectious diseases vol. 5,2 (2018): ofy016. doi: https://doi.org/10.1093/ofid/ofy016
Wang T, Kraft CS, Woodworth MH, Dhere T, Eaton ME. Fecal Microbiota Transplant for Refractory . Open Forum Infect Dis. 2018 Jan 15;5(2):ofy016. doi: 10.1093/ofid/ofy016. eCollection 2018 Feb. PMID: 29450212; PMCID: PMC5808805.
Copy Download .nbib Format: NLM
The Antibacterial Resistance Leadership Group: First Steps.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Murray BE, Jezek A.
PMID: 28350895
Clin Infect Dis. 2017 Mar 15;64:S1-S2. doi: 10.1093/cid/ciw823.

No abstract available.

Cite
Murray BE, Jezek A. The Antibacterial Resistance Leadership Group: First Steps. Clin Infect Dis. 2017;64:S1-S2doi: 10.1093/cid/ciw823.
Murray, B. E., & Jezek, A. (2017). The Antibacterial Resistance Leadership Group: First Steps. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 64S1-S2. https://doi.org/10.1093/cid/ciw823
Murray, Barbara E, and Jezek, Amanda. "The Antibacterial Resistance Leadership Group: First Steps." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 64 (2017): S1-S2. doi: https://doi.org/10.1093/cid/ciw823
Murray BE, Jezek A. The Antibacterial Resistance Leadership Group: First Steps. Clin Infect Dis. 2017 Mar 15;64:S1-S2. doi: 10.1093/cid/ciw823. PMID: 28350895; PMCID: PMC7526760.
Copy Download .nbib Format: NLM
Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes.

Statistics in biopharmaceutical research

Hamasaki T, Asakura K, Evans SR, Sugimoto T, Sozu T.
PMID: 25844122
Stat Biopharm Res. 2015;7(1):36-54. doi: 10.1080/19466315.2014.1003090.

We discuss the decision-making frameworks for clinical trials with multiple co-primary endpoints in a group-sequential setting. The decision-making frameworks can account for flexibilities such as a varying number of analyses, equally or unequally spaced increments of information and fixed...

Cite
Hamasaki T, Asakura K, Evans SR, et al. Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes. Stat Biopharm Res. 2015;7(1):36-54doi: 10.1080/19466315.2014.1003090.
Hamasaki, T., Asakura, K., Evans, S. R., Sugimoto, T., & Sozu, T. (2015). Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes. Statistics in biopharmaceutical research, 7(1), 36-54. https://doi.org/10.1080/19466315.2014.1003090
Hamasaki, Toshimitsu, et al. "Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes." Statistics in biopharmaceutical research vol. 7,1 (2015): 36-54. doi: https://doi.org/10.1080/19466315.2014.1003090
Hamasaki T, Asakura K, Evans SR, Sugimoto T, Sozu T. Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes. Stat Biopharm Res. 2015;7(1):36-54. doi: 10.1080/19466315.2014.1003090. PMID: 25844122; PMCID: PMC4382106.
Copy Download .nbib Format: NLM
Polymyxins: To Combine or Not to Combine?.

Antibiotics (Basel, Switzerland)

Perez F, El Chakhtoura NG, Yasmin M, Bonomo RA.
PMID: 30974813
Antibiotics (Basel). 2019 Apr 10;8(2). doi: 10.3390/antibiotics8020038.

Polymyxins have been a mainstay for the treatment of extensively drug resistant (XDR) Gram-negative bacteria for the past two decades. Many questions regarding the clinical use of polymyxins have been answered, but whether the administration of polymyxins in combination...

Cite
Perez F, El Chakhtoura NG, Yasmin M, et al. Polymyxins: To Combine or Not to Combine?. Antibiotics (Basel). 2019;8(2)doi: 10.3390/antibiotics8020038.
Perez, F., El Chakhtoura, N. G., Yasmin, M., & Bonomo, R. A. (2019). Polymyxins: To Combine or Not to Combine?. Antibiotics (Basel, Switzerland), 8(2), . https://doi.org/10.3390/antibiotics8020038
Perez, Federico, et al. "Polymyxins: To Combine or Not to Combine?." Antibiotics (Basel, Switzerland) vol. 8,2 (2019). doi: https://doi.org/10.3390/antibiotics8020038
Perez F, El Chakhtoura NG, Yasmin M, Bonomo RA. Polymyxins: To Combine or Not to Combine?. Antibiotics (Basel). 2019 Apr 10;8(2). doi: 10.3390/antibiotics8020038. PMID: 30974813; PMCID: PMC6627991.
Copy Download .nbib Format: NLM
Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by .

Open forum infectious diseases

Kanwar A, Marshall SH, Perez F, Tomas M, Jacobs MR, Hujer AM, Domitrovic TN, Rudin SD, Rojas LJ, Kreiswirth BN, Chen L, Quinones-Mateu M, van Duin D, Bonomo RA.
PMID: 30014001
Open Forum Infect Dis. 2018 Apr 23;5(4):ofy054. doi: 10.1093/ofid/ofy054. eCollection 2018 Apr.

We report the emergence of colistin resistance in

Cite
Kanwar A, Marshall SH, Perez F, et al. Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by . Open Forum Infect Dis. 2018;5(4):ofy054doi: 10.1093/ofid/ofy054.
Kanwar, A., Marshall, S. H., Perez, F., Tomas, M., Jacobs, M. R., Hujer, A. M., Domitrovic, T. N., Rudin, S. D., Rojas, L. J., Kreiswirth, B. N., Chen, L., Quinones-Mateu, M., van Duin, D., Bonomo, R. A. (2018). Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by . Open forum infectious diseases, 5(4), ofy054. https://doi.org/10.1093/ofid/ofy054
Kanwar, Anubhav, et al. "Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by ." Open forum infectious diseases vol. 5,4 (2018): ofy054. doi: https://doi.org/10.1093/ofid/ofy054
Kanwar A, Marshall SH, Perez F, Tomas M, Jacobs MR, Hujer AM, Domitrovic TN, Rudin SD, Rojas LJ, Kreiswirth BN, Chen L, Quinones-Mateu M, van Duin D, Bonomo RA. Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by . Open Forum Infect Dis. 2018 Apr 23;5(4):ofy054. doi: 10.1093/ofid/ofy054. eCollection 2018 Apr. PMID: 30014001; PMCID: PMC5913667.
Copy Download .nbib Format: NLM
Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?.

Open forum infectious diseases

Tamma PD, Pierce VM, Cosgrove SE, Lautenbach E, Harris A, Rayapati D, Han JH.
PMID: 29992175
Open Forum Infect Dis. 2018 Jun 08;5(6):ofy139. doi: 10.1093/ofid/ofy139. eCollection 2018 Jun.

BACKGROUND: In 2010, the Clinical Laboratory and Standards Institute recommended a 3-fold lowering of ceftriaxone breakpoints to 1 mcg/mL for METHODS: A retrospective cohort study was conducted at 3 large academic medical centers and included patients with RESULTS: Propensity...

Cite
Tamma PD, Pierce VM, Cosgrove SE, et al. Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?. Open Forum Infect Dis. 2018;5(6):ofy139doi: 10.1093/ofid/ofy139.
Tamma, P. D., Pierce, V. M., Cosgrove, S. E., Lautenbach, E., Harris, A., Rayapati, D., & Han, J. H. (2018). Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?. Open forum infectious diseases, 5(6), ofy139. https://doi.org/10.1093/ofid/ofy139
Tamma, Pranita D, et al. "Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?." Open forum infectious diseases vol. 5,6 (2018): ofy139. doi: https://doi.org/10.1093/ofid/ofy139
Tamma PD, Pierce VM, Cosgrove SE, Lautenbach E, Harris A, Rayapati D, Han JH. Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?. Open Forum Infect Dis. 2018 Jun 08;5(6):ofy139. doi: 10.1093/ofid/ofy139. eCollection 2018 Jun. PMID: 29992175; PMCID: PMC6022551.
Copy Download .nbib Format: NLM
On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes.

Contemporary clinical trials

Hamasaki T, Hung HMJ, Hsiao CF, Evans SR.
PMID: 33309946
Contemp Clin Trials. 2021 Feb;101:106244. doi: 10.1016/j.cct.2020.106244. Epub 2020 Dec 09.

We investigate selection of critical boundary functions for testing the hypotheses of two time-to-event outcomes as both primary endpoints or a primary and a secondary endpoint in group-sequential clinical trials, where (1) the effect sizes of endpoints are unequal,...

Cite
Hamasaki T, Hung HMJ, Hsiao CF, et al. On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes. Contemp Clin Trials. 2020;101:106244doi: 10.1016/j.cct.2020.106244.
Hamasaki, T., Hung, H. M. J., Hsiao, C. F., & Evans, S. R. (2021). On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes. Contemporary clinical trials, 101106244. https://doi.org/10.1016/j.cct.2020.106244
Hamasaki, Toshimitsu, et al. "On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes." Contemporary clinical trials vol. 101 (2021): 106244. doi: https://doi.org/10.1016/j.cct.2020.106244
Hamasaki T, Hung HMJ, Hsiao CF, Evans SR. On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes. Contemp Clin Trials. 2021 Feb;101:106244. doi: 10.1016/j.cct.2020.106244. Epub 2020 Dec 09. PMID: 33309946; PMCID: PMC7954908.
Copy Download .nbib Format: NLM
Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-2017) in relation to phylogenetic background, sequence type 131 subclones, bla.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

Johnston BD, Thuras P, Porter SB, Clabots C, Johnson JR.
PMID: 33893571
Eur J Clin Microbiol Infect Dis. 2021 Oct;40(10):2069-2075. doi: 10.1007/s10096-021-04256-9. Epub 2021 Apr 23.

Extended-spectrum cephalosporin-resistant Escherichia coli (ESCREC) are a growing threat. Leading ESCREC lineages include sequence type ST131, especially its (bla

Cite
Johnston BD, Thuras P, Porter SB, et al. Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-2017) in relation to phylogenetic background, sequence type 131 subclones, bla. Eur J Clin Microbiol Infect Dis. 2021;40(10):2069-2075doi: 10.1007/s10096-021-04256-9.
Johnston, B. D., Thuras, P., Porter, S. B., Clabots, C., & Johnson, J. R. (2021). Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-2017) in relation to phylogenetic background, sequence type 131 subclones, bla. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 40(10), 2069-2075. https://doi.org/10.1007/s10096-021-04256-9
Johnston, Brian D, et al. "Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-2017) in relation to phylogenetic background, sequence type 131 subclones, bla." European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology vol. 40,10 (2021): 2069-2075. doi: https://doi.org/10.1007/s10096-021-04256-9
Johnston BD, Thuras P, Porter SB, Clabots C, Johnson JR. Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-2017) in relation to phylogenetic background, sequence type 131 subclones, bla. Eur J Clin Microbiol Infect Dis. 2021 Oct;40(10):2069-2075. doi: 10.1007/s10096-021-04256-9. Epub 2021 Apr 23. PMID: 33893571; PMCID: PMC8449799.
Copy Download .nbib Format: NLM
Hospital Infection Control: .

Clinics in colon and rectal surgery

Turner NA, Anderson DJ.
PMID: 32104163
Clin Colon Rectal Surg. 2020 Mar;33(2):98-108. doi: 10.1055/s-0040-1701234. Epub 2020 Feb 25.

No abstract available.

Cite
Turner NA, Anderson DJ. Hospital Infection Control: . Clin Colon Rectal Surg. 2020;33(2):98-108doi: 10.1055/s-0040-1701234.
Turner, N. A., & Anderson, D. J. (2020). Hospital Infection Control: . Clinics in colon and rectal surgery, 33(2), 98-108. https://doi.org/10.1055/s-0040-1701234
Turner, Nicholas A, and Anderson, Deverick J. "Hospital Infection Control: ." Clinics in colon and rectal surgery vol. 33,2 (2020): 98-108. doi: https://doi.org/10.1055/s-0040-1701234
Turner NA, Anderson DJ. Hospital Infection Control: . Clin Colon Rectal Surg. 2020 Mar;33(2):98-108. doi: 10.1055/s-0040-1701234. Epub 2020 Feb 25. PMID: 32104163; PMCID: PMC7042016.
Copy Download .nbib Format: NLM
Photo Quiz: Bilateral Necrotizing Pneumonia in a 30-Year-Old Woman, a Hairy Situation.

Journal of clinical microbiology

Almulhim AM, Vellozzi-Averhoff CM, Howard-Anderson J, Babiker A, Kraft CS.
PMID: 33087544
J Clin Microbiol. 2020 Oct 21;58(11). doi: 10.1128/JCM.00451-20. Print 2020 Oct 21.

No abstract available.

Cite
Almulhim AM, Vellozzi-Averhoff CM, Howard-Anderson J, et al. Photo Quiz: Bilateral Necrotizing Pneumonia in a 30-Year-Old Woman, a Hairy Situation. J Clin Microbiol. 2020;58(11)doi: 10.1128/JCM.00451-20.
Almulhim, A. M., Vellozzi-Averhoff, C. M., Howard-Anderson, J., Babiker, A., & Kraft, C. S. (2020). Photo Quiz: Bilateral Necrotizing Pneumonia in a 30-Year-Old Woman, a Hairy Situation. Journal of clinical microbiology, 58(11), . https://doi.org/10.1128/JCM.00451-20
Almulhim, Abdulaziz M, et al. "Photo Quiz: Bilateral Necrotizing Pneumonia in a 30-Year-Old Woman, a Hairy Situation." Journal of clinical microbiology vol. 58,11 (2020). doi: https://doi.org/10.1128/JCM.00451-20
Almulhim AM, Vellozzi-Averhoff CM, Howard-Anderson J, Babiker A, Kraft CS. Photo Quiz: Bilateral Necrotizing Pneumonia in a 30-Year-Old Woman, a Hairy Situation. J Clin Microbiol. 2020 Oct 21;58(11). doi: 10.1128/JCM.00451-20. Print 2020 Oct 21. PMID: 33087544; PMCID: PMC7587113.
Copy Download .nbib Format: NLM
Rapid, Sample-to-Answer Host Gene Expression Test to Diagnose Viral Infection.

Open forum infectious diseases

Tsalik EL, Khine A, Talebpour A, Samiei A, Parmar V, Burke TW, Mcclain MT, Ginsburg GS, Woods CW, Henao R, Alavie T.
PMID: 34150923
Open Forum Infect Dis. 2019 Oct 30;6(11):ofz466. doi: 10.1093/ofid/ofz466. eCollection 2019 Nov.

OBJECTIVE: Distinguishing bacterial, viral, or other etiologies of acute illness is diagnostically challenging with significant implications for appropriate antimicrobial use. Host gene expression offers a promising approach, although no clinically useful test has been developed yet to accomplish this....

Cite
Tsalik EL, Khine A, Talebpour A, et al. Rapid, Sample-to-Answer Host Gene Expression Test to Diagnose Viral Infection. Open Forum Infect Dis. 2019;6(11):ofz466doi: 10.1093/ofid/ofz466.
Tsalik, E. L., Khine, A., Talebpour, A., Samiei, A., Parmar, V., Burke, T. W., Mcclain, M. T., Ginsburg, G. S., Woods, C. W., Henao, R., & Alavie, T. (2019). Rapid, Sample-to-Answer Host Gene Expression Test to Diagnose Viral Infection. Open forum infectious diseases, 6(11), ofz466. https://doi.org/10.1093/ofid/ofz466
Tsalik, Ephraim L, et al. "Rapid, Sample-to-Answer Host Gene Expression Test to Diagnose Viral Infection." Open forum infectious diseases vol. 6,11 (2019): ofz466. doi: https://doi.org/10.1093/ofid/ofz466
Tsalik EL, Khine A, Talebpour A, Samiei A, Parmar V, Burke TW, Mcclain MT, Ginsburg GS, Woods CW, Henao R, Alavie T. Rapid, Sample-to-Answer Host Gene Expression Test to Diagnose Viral Infection. Open Forum Infect Dis. 2019 Oct 30;6(11):ofz466. doi: 10.1093/ofid/ofz466. eCollection 2019 Nov. PMID: 34150923; PMCID: PMC8210837.
Copy Download .nbib Format: NLM
Evaluating Anti-Infective Drugs in the Resistant Pathogen Setting: Can we Use External Controls?.

Statistical communications in infectious diseases

Evans SR, Powers J.
PMID: 28757914
Stat Commun Infect Dis. 2017;9(1). doi: 10.1515/scid-2016-0003. Epub 2017 Mar 14.

Decreased efficacy of antibiotics due to resistant pathogens has created a need for the development of more effective medical interventions. Despite the increasing prevalence of pathogens resistant to one or more drugs, identifying and enrolling participants into clinical trials...

Cite
Evans SR, Powers J. Evaluating Anti-Infective Drugs in the Resistant Pathogen Setting: Can we Use External Controls?. Stat Commun Infect Dis. 2017;9(1)doi: 10.1515/scid-2016-0003.
Evans, S. R., & Powers, J. (2017). Evaluating Anti-Infective Drugs in the Resistant Pathogen Setting: Can we Use External Controls?. Statistical communications in infectious diseases, 9(1), . https://doi.org/10.1515/scid-2016-0003
Evans, Scott R, and Powers, John. "Evaluating Anti-Infective Drugs in the Resistant Pathogen Setting: Can we Use External Controls?." Statistical communications in infectious diseases vol. 9,1 (2017). doi: https://doi.org/10.1515/scid-2016-0003
Evans SR, Powers J. Evaluating Anti-Infective Drugs in the Resistant Pathogen Setting: Can we Use External Controls?. Stat Commun Infect Dis. 2017;9(1). doi: 10.1515/scid-2016-0003. Epub 2017 Mar 14. PMID: 28757914; PMCID: PMC5529043.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 43 entries